Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 16/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363729 | 0.93 | POLB (0.38) | POLBHTR2CHTR2B | |
| SCHEMBL24987227 | 0.92 | AR (0.36) | ARHRH1KCNH2POLBCYP3A4 | |
| SCHEMBL23717502 | 0.92 | AR (0.35) | ARHRH1KCNH2POLB | |
| SCHEMBL24363615 | 0.86 | MEN1 (0.37) | — | |
| SCHEMBL23717045 | 0.85 | POLB (0.37) | POLBHTR2CHTR2B | |
| SCHEMBL24363658 | 0.84 | POLB (0.39) | POLBHTR2CHTR2B | |
| SCHEMBL23905701 | 0.84 | AR (0.35) | ARHRH1KCNH2POLBCYP3A4 | |
| SCHEMBL23683773 | 0.84 | AR (0.35) | ARHRH1KCNH2POLBCYP3A4 | |
| SCHEMBL24987499 | 0.84 | AR (0.33) | ARPOLB | |
| SCHEMBL24345438 | 0.83 | POLB (0.38) | POLBHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | AR 4623/4885HRH1 21/4885KCNH2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.